Biora Therapeutics To Present Preclinical Data On BioJet Systemic Oral Delivery Platform
Portfolio Pulse from Benzinga Newsdesk
Biora Therapeutics is set to present preclinical data on its BioJet Systemic Oral Delivery Platform, a technology designed to improve the oral delivery of biologic drugs.
June 08, 2023 | 1:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biora Therapeutics will present preclinical data on its BioJet Systemic Oral Delivery Platform, which could potentially improve the oral delivery of biologic drugs.
The presentation of preclinical data on Biora Therapeutics' BioJet Systemic Oral Delivery Platform is likely to generate interest in the company's technology and its potential applications. This could lead to increased investor confidence and a positive short-term impact on BIOR's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100